PHIO · Phio Pharmaceuticals Corp
United States · RS rating 29 · As of 2026-11-03
| Price | 0.90 USD |
|---|---|
| 1-day change | +2.6% |
| RS rating (overall / 1M / 3M / 12M) | 29 / 37 / 37 / 19 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 20 / 10 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -5.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +51.5% |
| Market cap (USD) | $14.3M |